Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO).

MLA

Kahl, C., et al. “Long-Term Follow-up of the AML97 Study for Patients Aged 60 Years and above with Acute Myeloid Leukaemia: A Study of the East German Haematology and Oncology Study Group (OSHO).” Journal of Cancer Research and Clinical Oncology, vol. 142, no. 1, Jan. 2016, pp. 305–15. EBSCOhost, https://doi.org/10.1007/s00432-015-2045-8.

APA

Kahl, C., Krahl, R., Becker, C., Al-Ali, H. K., Sayer, H. G., Schulze, A., Herold, M., Hänel, M., Scholl, S., Hochhaus, A., Uharek, L., Maschmeyer, G., Haehling, D., Junghanß, C., Peter, N., Kämpfe, D., Kettner, E., Heinicke, T., Fischer, T., … Niederwieser, D. (2016). Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO). Journal of Cancer Research and Clinical Oncology, 142(1), 305–315. https://doi.org/10.1007/s00432-015-2045-8

Chicago

Kahl, C, R Krahl, C Becker, H K Al-Ali, H G Sayer, A Schulze, M Herold, et al. 2016. “Long-Term Follow-up of the AML97 Study for Patients Aged 60 Years and above with Acute Myeloid Leukaemia: A Study of the East German Haematology and Oncology Study Group (OSHO).” Journal of Cancer Research and Clinical Oncology 142 (1): 305–15. doi:10.1007/s00432-015-2045-8.